Polaris Venture Management Co. V L.L.C. Acquires Shares of 311,492 X4 Pharmaceuticals Inc (NASDAQ:XFOR)

Polaris Venture Management Co. V L.L.C. purchased a new stake in shares of X4 Pharmaceuticals Inc (NASDAQ:XFOR) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 311,492 shares of the company’s stock, valued at approximately $5,423,000. X4 Pharmaceuticals accounts for 4.6% of Polaris Venture Management Co. V L.L.C.’s holdings, making the stock its 6th biggest position. Polaris Venture Management Co. V L.L.C. owned approximately 2.51% of X4 Pharmaceuticals at the end of the most recent reporting period.

Shares of XFOR traded down $1.16 during trading on Friday, reaching $13.51. 11,344 shares of the company traded hands, compared to its average volume of 51,301. X4 Pharmaceuticals Inc has a twelve month low of $6.90 and a twelve month high of $29.46. The business’s 50-day moving average is $14.93. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.59 and a quick ratio of 1.59.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($6.67) earnings per share for the quarter. As a group, sell-side analysts expect that X4 Pharmaceuticals Inc will post -4.08 earnings per share for the current fiscal year.

Several equities analysts have issued reports on the stock. Stifel Nicolaus increased their price objective on shares of Vail Resorts from $219.00 to $230.00 and gave the company a “hold” rating in a report on Friday, June 7th. Cowen set a $27.00 price target on shares of Puma Biotechnology and gave the stock a “hold” rating in a research note on Wednesday, June 5th. Finally, Canaccord Genuity reissued a “hold” rating and issued a GBX 860 ($11.24) price target on shares of Galliford Try in a research note on Tuesday, May 21st.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Featured Story: What does relative strength index mean?

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.